ARWR
Arrowhead Pharmaceuticals, Inc.
ARWR trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over ARWR overall, supported by stronger fundamentals and lower modeled downside.
ARWR Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
ARWR's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ARWR PE Valuation
ARWR has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ARWR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect ARWR's losses to grow, with revenue declining. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ARWR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$5.11 | -$5.10 |
| Q2 2026 | -$2.18 | -$0.92 |
| Q1 2026 | -$2.08 | -$0.70 |
| Q4 2025 | $1.60 | +$6.75 |
| Q3 2025 | -$0.01 | +$4.99 |
| Q2 2025 | -$1.26 | +$3.40 |
| Q1 2025 | -$1.38 | +$2.86 |
| Q4 2024 | -$5.15 | -$2.38 |
ARWR lost $5.11 per share over the past year, and its loss has widened in each of the last three quarters.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ARWR on earnings quality, reporting a profit while its opponent remains loss making.
ARWR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $37.8M | -85% |
| Q2 2026 | $75.3M | +171% |
| Q1 2026 | $73.7M | -86% |
| Q4 2025 | $264M | +10461% |
| Q4 2024 | $2.5M | -30% |
| Q4 2023 | $3.6M | -94% |
| Q3 2023 | $16.1M | -49% |
| Q2 2023 | $15.8M | -51% |
ARWR's revenue has slid since its 2025 peak: $38M last quarter, down 85% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1155% | -1173 points |
| Q2 2026 | -226% | +370 points |
| Q1 2026 | -192% | -262 points |
| Q4 2025 | 15% | +6472 points |
| Q3 2025 | 17% | N/A |
| Q2 2025 | -596% | N/A |
| Q1 2025 | 70% | N/A |
| Q4 2024 | -6456% | -2611 points |
ARWR's operating margin was −1155% last quarter, down 1172 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ARWR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ARWR on profitability, with a higher operating margin.
ARWR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$195.8M | -1606% |
| Q2 2026 | -$181.3M | -$24.2M |
| Q1 2026 | $81.9M | -82% |
| Q4 2025 | $11.3M | +$165.1M |
| Q3 2025 | $13M | +$174.5M |
| Q2 2025 | -$157.1M | -$27.2M |
| Q1 2025 | $454.8M | +$581.2M |
| Q4 2024 | -$153.8M | +$32.7M |
ARWR has burned cash in most quarters: −$284M over the past year, against $157M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ARWR on cash generation, producing positive trailing cash flow while its opponent burns cash.
ARWR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -1.7M shares |
| 1 year | +5.9% | +7.9M shares |
| 3 years | +33% | +34.9M shares |
| 5 years | +37% | +37.9M shares |
| Available history | +46% | +44.5M shares |
ARWR has 142M diluted shares, up 5.9% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ARWR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ARWR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 0.0x | Very low |
| Q3 2025 | 0.2x | Very low |
| Q1 2020 | -51.3x | Net Cash |
| Q4 2019 | -9.3x | Net Cash |
ARWR has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ARWR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.8 | Oversold |
| Stochastic | 6.6 | Oversold |
ARWR's weekly RSI is 30 (oversold) and its Stochastic is 7 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ARWR PE vs Healthcare Sector
| Metric | ARWR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ARWR has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ARWR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $59.0 | 20% below |
| 20 week MA | $73.0 | 35% below |
| 50 week MA | $70.0 | 33% below |
| 100 week MA | $46.1 | 2.3% above |
| 200 week MA | $37.1 | 27% above |
ARWR has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 27% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ARWR on trend strength, trading above more of its moving averages.
ARWR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $64.9 | $84.2 | +30% |
| 2021 | $84.2 | $70.3 | -17% |
| 2022 | $70.3 | $38.3 | -45% |
| 2023 | $38.3 | $30.6 | -20% |
| 2024 | $30.6 | $19.0 | -38% |
| 2025 | $19.0 | $70.2 | +270% |
| 2026 YTD | $70.2 | $47.2 | -33% |
ARWR's yearly returns have swung widely, from +270% in 2025 to −45% in 2022. It's down 33% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ARWR on returns for 2026, with the stronger performance.